Dr. Patrick Soon-Shiong on BioShield and Cancer Remission

The BioShield Concept

• 💡 Dr. Patrick Soon-Shiong developed "BioShield," a T-cell-based immunotherapy designed to educate the body's immune system to fight disease.
• 🎯 This approach is described as a cancer vaccine that trains T-cells to recognize and kill cancer cells, distinguishing it from traditional antibody-based vaccines.
• 🧠 The core concept involves creating memory T-cells that reside in bone marrow, activating when needed to eliminate harmful cells.

Funding and Development

• 💰 Soon-Shiong personally funded the research and development of these therapies, investing $3 billion of his own money after selling his companies.
• ✅ He emphasized that no government funding was received, which he believes provided freedom and liberation in his research.

Cancer Prevention Trials

• 🔬 BioShield is currently in clinical trials for Lynch syndrome, a genetic predisposition that significantly increases the risk of various cancers, with 100 patients already enrolled for prevention.
• 📈 This initiative represents one of the first rigorous trials focused on cancer prevention using this specific T-cell education approach.

Documented Treatment Successes

• 💊 The BioShield-related drug, ANKTIVA, received FDA approval in 2024 for bladder cancer.
• ✨ Patients with advanced bladder cancer who had failed previous treatments achieved complete remission, with some remaining disease-free for 9 years.
• 🎗️ Other notable cases include patients with metastatic pancreatic cancer achieving 5 years disease-free, and complete responses in Merkel cell carcinoma and severe head and neck tumors.

Mechanism and Impact

• 🧬 The therapy works by dynamically activating the body's natural killer (NK) cells and T-cells to target and eliminate diseased cells.
• 🚀 These treatments have led to complete remission in severe cancer cases, even for patients previously deemed terminal and facing hospice care.